FDA advice for HBV (hepatitis B virus) assays producers:
This article was originally published in Clinica
Executive Summary
The US FDA has issued draft guidance providing recommendations for manufacturers who make assays to detect the presence of hepatitis B surface antigen in blood, blood components and source plasma donations. The guidance lowers the assay's minimum sensitivity for detecting the virus to 0.50 ng HBsAG/ml from 1.0 ng HBsAG/ml, the threshold used by industry since 1996. The draft was published in the Federal Register on April 11. Comments are due by July 10.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.